See more : Ichimasa Kamaboko Co., Ltd. (2904.T) Income Statement Analysis – Financial Results
Complete financial analysis of Glenmark Pharmaceuticals Limited (GLENMARK.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Glenmark Pharmaceuticals Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Quantum eMotion Corp. (QNC.V) Income Statement Analysis – Financial Results
- Yeahka Limited (YHEKF) Income Statement Analysis – Financial Results
- Kish Bancorp, Inc. (KISB) Income Statement Analysis – Financial Results
- Sekur Private Data Ltd. (SWISF) Income Statement Analysis – Financial Results
- Williams Industrial Services Group Inc. (WLMSQ) Income Statement Analysis – Financial Results
Glenmark Pharmaceuticals Limited (GLENMARK.BO)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.glenmarkpharma.com
About Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, Japan, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its product pipeline includes ISB 2001, a BCMA x CD38 x CD3 trispecific antibody, which is in Phase 1 clinical trial for oncology; GRC 39815, a retinoid-related orphan receptor gamma t inverse agonist, which is in Phase 1 clinical trial for the treatment of chronic obstructive pulmonary disease; and GRC 54276, a hematopoietic progenitor kinase 1 inhibitor, which is in Phase 1 clinical trial for the treatment of solid tumors. Its pipeline also comprises ISB 1342, CD38 X CD3 bispecific antibody, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma; ISB 1442, a CD38 x CD47 immune cell engager, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma; ISB 880, a IL-1RAP antibody, which is in Phase 1 clinical trial for the treatment of autoimmune diseases; and ISB 830, a OX40 antagonist, which is in Phase 2 clinical trial for the treatment of atopic dermatitis. In addition, the company offers Ryaltris nasal spray for the treatment of seasonal allergic rhinitis. Glenmark Pharmaceuticals Limited was incorporated in 1977 and is based in Mumbai, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 118.13B | 127.25B | 121.74B | 108.06B | 103.97B | 97.05B | 89.44B | 88.64B | 73.70B | 65.22B | 59.24B | 49.69B | 40.21B | 29.49B | 25.01B | 21.16B | 20.09B | 12.52B | 7.58B | 6.12B | 3.81B |
| Cost of Revenue | 85.54B | 48.83B | 47.78B | 39.97B | 40.35B | 37.64B | 34.15B | 28.95B | 25.72B | 21.28B | 20.54B | 17.99B | 13.45B | 9.92B | 10.19B | 8.75B | 6.76B | 4.57B | 3.82B | 2.71B | 1.79B |
| Gross Profit | 32.59B | 78.42B | 73.96B | 68.09B | 63.62B | 59.41B | 55.29B | 59.69B | 47.98B | 43.93B | 38.70B | 31.70B | 26.75B | 19.57B | 14.81B | 12.41B | 13.33B | 7.94B | 3.76B | 3.41B | 2.01B |
| Gross Profit Ratio | 27.59% | 61.63% | 60.75% | 63.01% | 61.19% | 61.22% | 61.82% | 67.34% | 65.10% | 67.36% | 65.33% | 63.80% | 66.54% | 66.37% | 59.24% | 58.64% | 66.36% | 63.45% | 49.61% | 55.65% | 52.89% |
| Research & Development | 12.26B | 12.50B | 12.79B | 13.19B | 13.21B | 14.48B | 12.25B | 12.62B | 8.18B | 6.01B | 6.00B | 4.12B | 0.00 | 0.00 | 772.76M | 882.70M | 757.73M | 432.61M | 263.34M | 341.19M | 248.07M |
| General & Administrative | 2.63B | 3.04B | 4.01B | 3.17B | 3.65B | 2.75B | 2.07B | 2.22B | 1.93B | 1.59B | 1.11B | 966.02M | 0.00 | 0.00 | 7.84B | 6.98B | 4.57B | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 10.92B | 11.54B | 8.96B | 9.43B | 10.06B | 8.71B | 7.63B | 8.43B | 6.58B | 4.65B | 3.65B | 3.79B | 0.00 | 0.00 | 0.00 | 0.00 | 4.57B | 3.25B | 2.12B | 1.51B | 1.07B |
| SG&A | 13.55B | 14.58B | 12.97B | 12.60B | 13.71B | 11.46B | 9.70B | 10.65B | 8.51B | 6.24B | 4.75B | 4.75B | 0.00 | 0.00 | 7.84B | 6.98B | 4.57B | 3.25B | 2.12B | 1.51B | 1.07B |
| Other Expenses | 0.00 | 712.92M | 688.35M | 468.65M | 162.93M | 267.61M | 129.59M | 165.89M | 115.39M | 204.64M | 48.40M | 64.85M | 92.61M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 46.95B | 61.74B | 55.56B | 50.93B | 50.80B | 46.81B | 42.66B | 45.09B | 36.35B | 36.31B | 29.86B | 22.49B | 20.59B | 13.19B | 9.33B | 7.15B | 5.59B | 3.94B | 2.49B | 1.97B | 1.40B |
| Cost & Expenses | 111.63B | 110.57B | 103.34B | 90.90B | 91.15B | 84.45B | 76.80B | 74.04B | 62.06B | 57.59B | 50.40B | 40.48B | 34.04B | 23.11B | 19.53B | 15.90B | 12.35B | 8.52B | 6.31B | 4.68B | 3.19B |
| Interest Income | 0.00 | 227.66M | 94.35M | 26.47M | 46.76M | 27.00M | 89.36M | 180.69M | 75.80M | 14.31M | 66.44M | 42.62M | 89.12M | 38.97M | 0.00 | 0.00 | 78.74M | 14.18M | 34.48M | 8.42M | 0.00 |
| Interest Expense | 5.16B | 3.50B | 2.98B | 3.53B | 3.77B | 3.35B | 2.86B | 2.37B | 1.79B | 1.90B | 1.89B | 1.60B | 1.47B | 1.60B | 1.64B | 1.40B | 710.42M | 398.26M | 181.67M | 172.63M | 100.58M |
| Depreciation & Amortization | 5.82B | 6.11B | 4.87B | 4.44B | 4.17B | 3.26B | 3.54B | 5.77B | 2.69B | 2.60B | 2.17B | 1.27B | 978.28M | 946.78M | 1.21B | 1.03B | 716.80M | 422.59M | 232.34M | 164.23M | 110.93M |
| EBITDA | 11.34B | 11.58B | 22.26B | 21.79B | 18.91B | 15.86B | 17.06B | 20.74B | 14.47B | 10.44B | 11.02B | 10.21B | 7.33B | 7.37B | 6.69B | 5.12B | 8.46B | 4.42B | 1.50B | 1.60B | 725.74M |
| EBITDA Ratio | 9.60% | 20.36% | 20.48% | 19.75% | 17.88% | 18.48% | 19.11% | 23.38% | 19.71% | 16.01% | 18.61% | 20.65% | 18.22% | 24.98% | 26.73% | 29.73% | 42.12% | 35.32% | 19.80% | 26.16% | 19.07% |
| Operating Income | 6.31B | 17.12B | 18.82B | 16.65B | 12.15B | 15.90B | 13.43B | 14.79B | 11.76B | 7.83B | 8.79B | 8.95B | 6.26B | 6.38B | 5.48B | 5.26B | 7.11B | 3.61B | 1.12B | 1.27B | 514.23M |
| Operating Income Ratio | 5.34% | 13.46% | 15.46% | 15.41% | 11.68% | 16.38% | 15.02% | 16.69% | 15.96% | 12.01% | 14.84% | 18.01% | 15.56% | 21.64% | 21.91% | 24.87% | 35.41% | 28.87% | 14.79% | 20.80% | 13.51% |
| Total Other Income/Expenses | -5.95B | -25.72B | -21.19B | -15.86B | -15.29B | -7.40B | -1.97B | -2.19B | -1.71B | -1.89B | -1.82B | -1.44B | -1.38B | -1.57B | -1.64B | -2.57B | -85.27M | 0.00 | -33.86M | 0.00 | 0.00 |
| Income Before Tax | 364.95M | 8.68B | 14.41B | 13.82B | 10.96B | 13.01B | 10.67B | 12.60B | 10.05B | 5.94B | 6.97B | 7.39B | 4.88B | 4.82B | 3.84B | 2.69B | 7.11B | 3.61B | 1.12B | 1.27B | 514.23M |
| Income Before Tax Ratio | 0.31% | 6.82% | 11.84% | 12.79% | 10.54% | 13.40% | 11.93% | 14.22% | 13.63% | 9.11% | 11.76% | 14.87% | 12.14% | 16.33% | 15.35% | 12.71% | 35.41% | 28.87% | 14.79% | 20.80% | 13.51% |
| Income Tax Expense | 18.67B | 4.91B | 4.48B | 4.12B | 3.20B | 3.76B | 2.93B | 3.44B | 3.03B | 1.19B | 1.51B | 1.11B | 237.84M | 237.03M | 528.66M | 754.08M | 793.87M | 512.58M | 240.96M | 201.53M | 100.89M |
| Net Income | -15.02B | 2.97B | 9.42B | 9.70B | 7.76B | 9.25B | 7.74B | 9.16B | 7.02B | 4.75B | 5.42B | 6.20B | 4.60B | 4.58B | 3.31B | 1.93B | 6.32B | 3.10B | 879.76M | 1.07B | 413.61M |
| Net Income Ratio | -12.71% | 2.34% | 7.74% | 8.98% | 7.46% | 9.53% | 8.66% | 10.33% | 9.53% | 7.29% | 9.15% | 12.48% | 11.45% | 15.52% | 13.24% | 9.14% | 31.46% | 24.77% | 11.61% | 17.50% | 10.87% |
| EPS | -53.22 | 10.53 | 33.37 | 34.38 | 27.50 | 32.78 | 27.44 | 32.46 | 25.01 | 17.52 | 20.01 | 22.91 | 17.03 | 16.95 | 12.69 | 7.74 | 25.84 | 13.02 | 3.71 | 4.52 | 1.81 |
| EPS Diluted | -53.22 | 10.53 | 33.37 | 34.38 | 27.50 | 32.78 | 27.43 | 32.45 | 25.00 | 17.52 | 20.00 | 22.89 | 17.01 | 16.93 | 12.67 | 7.58 | 24.96 | 11.59 | 3.26 | 4.11 | 1.80 |
| Weighted Avg Shares Out | 282.16M | 282.17M | 282.17M | 282.17M | 282.17M | 282.17M | 282.17M | 282.17M | 280.73M | 271.26M | 271.03M | 270.69M | 270.38M | 270.04M | 260.76M | 250.03M | 244.62M | 238.12M | 237.33M | 237.16M | 228.71M |
| Weighted Avg Shares Out (Dil) | 282.18M | 282.17M | 282.17M | 282.17M | 282.17M | 282.18M | 282.21M | 282.25M | 280.79M | 271.36M | 271.15M | 270.88M | 270.64M | 270.46M | 261.32M | 255.26M | 253.24M | 267.56M | 269.61M | 260.80M | 229.81M |
Source: https://incomestatements.info
Category: Stock Reports